New antibiotic combo aims to cut treatment time for stubborn lung infection
NCT ID NCT07213765
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding the antibiotic contezolid to standard drugs can shorten treatment for Mycobacterium Avium Complex (MAC) lung disease. About 188 adults with the nodular bronchiectatic form of the disease will either receive contezolid plus standard therapy for 6 months, or standard therapy alone for 12 months. Researchers will check if the combination leads to faster clearance of bacteria and better quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Contezolid (an antibiotic) added to a standard regimen of azithromycin, ethambutol, and rifampicin
What this could lead to
If it works, this could lead to a shorter, more effective treatment for MAC lung disease, reducing the time patients need to take antibiotics.
What could go wrong
This is a Phase 4 trial with 188 participants, so results are not yet proven. Adding a new drug may cause side effects or not improve outcomes compared to standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYCOBACTERIUM AVIUM COMPLEX PULMONARY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Anhui Chest Hospital
RECRUITINGHefei, Anhui, China
-
Beijing Chest Hospital, Capital Medical University
RECRUITINGBeijing, Beijing Municipality, China
-
China-Japan Friendship Hospital
RECRUITINGBeijing, Beijing Municipality, China
-
Guangzhou Chest Hospital
NOT_YET_RECRUITINGGuangzhou, Guangdong, China
-
Jiangxi Chest Hospital
RECRUITINGNanchang, Jiangxi, China
-
Shanghai Pulmonary Hospital
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.